Truist raised the price target for the Edwards Lifesciences Corporation (NYSE:EW) stock to “a Buy”. The rating was released on April 13, 2022, according to finviz. The research report from Bernstein has upgraded the stock from Mkt Perform to Outperform, with a price target set at $135. The stock was resumed by BofA Securities, who disclosed in a research note on March 02, 2022, to Neutral and set the price objective to $130. In their research brief published February 02, 2022, UBS analysts upgraded the Edwards Lifesciences Corporation stock from Neutral to Buy with a price target of $126.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Edwards Lifesciences Corporation (NYSE:EW) raised 0.18% to close Thursday’s market session at $93.44, higher as compared to yesterday’s close. The stock price fluctuated between $91.52 and $94.5989 throughout the trading session with the volume trading being 3718727 shares, which represented a significant variation when compared to the three months average volume of 2.76 million shares. The firm’s stock price fluctuated -9.60% within the last five trades and -22.67% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -21.33% in the last 6 months and -15.55% was subtracted to its value over the previous 3 months. EW stock is trading at a margin of -16.03%, -16.89% and -18.75% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, EW deals in the Healthcare domain. The stock is trading -29.07 percent below its 52-week high and 7.01 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -10.5. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Edwards Lifesciences Corporation’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 32.60 percent and the profit margin is 28.70 percent, and the company has reported a gross margin of 76.60 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $59.74 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Edwards Lifesciences Corporation (NYSE:EW) is 38.30. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 32.74. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 11.15 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 9.94, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.10 percent of Edwards Lifesciences Corporation shares are owned by insiders, and 86.10 percent are held by financial institutions. Wood Larry L, the CVP, TAVR at Edwards Lifesciences Corporation (EW) has sold 7,242 shares of firm on May 10 at a price of $96.13 against the total amount of $0.7 million. In another inside trade, MUSSALLEM MICHAEL A, Chairman & CEO of Edwards Lifesciences Corporation (NYSE:EW) sold 32,550 shares of the firm on May 10 for a total worth of $3.09 million at a price of $94.82. An inside trade which took place on May 09, CVP, EMEA, Canada, Latin Amer of Edwards Lifesciences Corporation Lemercier Jean-Luc M sold 11,560 shares of firm against total price of $1.14 million at the cost of $98.24 per share.